Zenas BioPharma stock plunges over 50% after Phase 3 obexelimab trial results disappoint Wall Street, despite meeting all endpoints in rare autoimmune disease study.
Citi, H.C. Wainwright, JonesResearch, and LifeSci Capital share new ratings and price targets on Zenas BioPharma, Spruce Biosciences, Context Therapeutics, and Ovid Therapeutics.
Zenas BioPharma acquires global rights to orelabrutinib, an experimental multiple sclerosis drug from InnoCare Pharma, in a licensing deal worth over $2 billion with $120M funding secured.
